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ABSTRACT 
Purpose:  Brain  metastases  from  renal  cell  carcinoma  (RCC)  have  been  successfully  treated  with  stereotactic 
radiosurgery  (SRS).  Metastases  to  extra cranial  sites  may  be  treated  with  similar  success  using  stereotactic  body 
radiation therapy (SBRT), where image guidance allows for the delivery of precise high dose radiation in a few fractions. 
This paper reports the authors’ initial experience with image guided SBRT in treating primary and metastatic RCC. 
Materials and methods: The image guided Brainlab Novalis stereotactic system was used. Fourteen patients with 
23 extra cranial metastatic RCC lesions (orbits, head and neck, lung, mediastinum, sternum, clavicle, scapula, humerus, 
rib, spine and abdominal wall) and two patients with biopsy proven primary RCC (not surgical candidates) were treated 
with SBRT (24 40 Gy in 3 6 fractions over 1 2 weeks). All patients were immobilised in body cast or head and neck 
mask. Image guidance was used for all fractions. PET/CT images were fused with simulation CT images to assist in 
target  delineation  and  dose  determination.  SMART  (simultaneous  modulated  accelerated  radiation  therapy)  boost 
approach was adopted. 4D CT was utilised to assess tumour/organ motion and assist in determining planning target 
volume margins.  
Results:  Median  follow up  was  nine  months.  Thirteen  patients  (93%)  who  received  SBRT  to  extra cranial 
metastases achieved symptomatic relief. Two patients had local progression, yielding a local control rate of 87%. In the 
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two patients with primary RCC, tumour size remained unchanged but their pain improved, and their renal function was 
unchanged post SBRT. There were no significant treatment related side effects. 
Conclusion: Image guided SBRT provides excellent symptom palliation and local control without any significant 
toxicity. SBRT may represent a novel, non invasive, nephron sparing option for the treatment of primary RCC as well as 
extra cranial metastatic RCC. © 2007 Biomedical Imaging and Intervention Journal. All rights reserved. 




Renal  cell  carcinoma  (RCC)  is  traditionally 
considered  to  be  radio resistant  and  the  conventional 
dose fraction size of 1.8 2.0 Gy is thought to have little 
role  in  the  management  of  primary  RCC  especially  in 
terms  of  cure.  In  the  setting  of  metastatic  RCC, 
conventional  radiotherapy  has  been  an  effective 
palliative treatment in approximately 50% of patients [1]. 
More importantly, brain metastases from RCC have been 
successfully treated with stereotactic radiosurgery (SRS) 
with  local  control  rates  of  more  than  85%  [2 5].  The 
advances  in  technology  and  physics  in  radiation 
oncology  have  led  to  the  clinical  implementation  of 
image guided  radiation  therapy  (IGRT)  and  body 
stereotaxis. Thus, it is now possible to deliver very high 
and  biologically  potent  dose  to  the  tumours  extra 
cranially.  Therefore,  primary  RCC  as  well  as  RCC 
metastases  to  extra cranial  sites  may  be  treated  with 
similar success using stereotactic body radiation therapy 
(SBRT), where image guidance and stereotaxis allow for 
the  delivery  of  precise  high dose  radiation  in  a  few 
fractions  [6].  This  paper  reports  the  authors’  initial 
experience  with  SBRT  in  the  management  of  primary 
and metastatic RCC. 
MATERIALS AND METHODS 
Patient population 
This  is  a  retrospective  study  of  sixteen  patients 
(fourteen patients with metastatic RCC and status of post 
initial  nephrectomy,  and  two  medically  inoperable 
patients  with  co existing  primary  and  metastatic  RCC) 
treated  at  a  single  institution.  All  patients  signed  an 
informed consent prior to the simulation and delivery of 
SBRT.  The  twenty three  extra cranial  metastatic  RCC 
lesions in the fourteen patients included the orbits, head 
and neck, lung, mediastinum, sternum, clavicle, scapula, 
humerus, rib, spine and abdominal wall. The two patients 
with  biopsy proven  primary  RCC  were  not  candidates 
for nephrectomy because of multiple medical problems 
including cardiac and pulmonary morbidity. In addition 
to  the  primary  RCC,  they  also  had  metastatic  RCC 
involving various extracranial sites. All sixteen patients 
with  metastatic  RCC  involving  extracranial  sites  were 
referred  for  radiotherapy  because  of  local  symptoms 
especially pain. All of these patients have received some 
prior  systemic  treatment  regimens  consisting  of  IL2, 
interferon,  various  chemotherapeutic  agents,  targeted 
therapy  (such  as  sorafenib  and  sunitinib),  clinical  trial 
drugs  or  any  combinations.  They  did  not  receive  any 
concurrent systemic treatment with SBRT. Both of the 
medically  inoperable  patients  for  nephrectomy  were 
referred  because  they  were  not  candidates  for  any 
systemic  treatment  of  either  IL2  or  interferon.  Neither 
sorafenib nor sunitinib was approved for use by FDA at 
that  time.  They  both  had  pain  in  the  flank  originating 
from  the  primary  tumour.  The  concern  was  that  the 
primary RCC may progress and cause more pain as well 
as deterioration of renal function.  
SBRT simulation, target delineation, treatment planning 
and delivery 
IGRT linear accelerator/simulation 
SBRT  is  made  possible  with  the  technological 
advances  in  image guided  radiation  therapy  (IGRT). 
SBRT  makes  use  of  the  principles  of  stereotactic 
radiosurgery  (SRS)  to  provide  accurate  and  precise 
delivery of high dose radiation to targets in extracranial 
sites. The Brainlab Novalis system is an image guided, 
shaped beam  radio surgical  unit,  capable  of  using 
conformal arcs and intensity modulated radiation therapy 
(IMRT). It utilises stereoscopic X ray based localisation 
technology  for  high precision  non invasive  SBRT  to 
extracranial  targets.  (Figure  1a)  More  specifically,  the 
unit has the ability of corroborative image fusion of the 
digitally  reconstructed  image  from  CT  simulation  and 
orthogonal X ray imagery taken in the treatment position. 
(Figure  1b)  The  robotic  couch  allows  automated 
positioning  of  the  patients  to  the  best  match  of  the 
stereoscopic  images  to  the  planning  CT.  Verification 
images are taken after the patient is aligned. Shifts of less 
than 1 mm are ignored.  The unit is also equipped with a 
non invasive,  frameless  positioning  device  that  uses 
infrared,  passive  marker  technology  as  well  as  the 
micromultileaf  collimator  for  radiation  intensity 
modulation  and  beam  shaping.  Using  dynamic  shaped 
beam,  this  system  maximises  the  dose  to  irregularly 
shaped  lesions,  while  minimising  the  dose  to  the 
surrounding  normal  tissues.  During  simulation,  the 
patients  were  immobilised  in  a  head  and  neck  mask 
(Figure 2a) or body cast (Figure 2b) depending on the 
sites  irradiated.  A  PET/CT  was  performed  with  the 
patient  in  the  immobilisation  device  during  the  same 
simulation session to  facilitate the optimal  fusion  with 
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the  simulation  CT.  4D CT  was  also  performed  to 
evaluate tumour and organ motion on selected patients. 
Target delineation /organ motion/fiducial markers 
SBRT  target  delineation  generally  included  only 
gross tumour volume (GTV) as evidenced clinically and 
on imaging studies. The inclusion of PET/CT images to 
the  Novalis  BrainScan  further  refines  the  target 
delineation.  MR  images  were  also  fused  to  aid  target 
delineation especially in the  head and  neck, and spine 
regions. There was no true clinical target volume (CTV) 
representing  sub clinical  disease  involvement  that 
follows  the  ICRU  50  paradigm.  The  integration  of 
PET/CT images also allows for differential fraction size 
prescription/delivery,  i.e.  SMART  (simultaneous 
modulated  accelerated  radiation  therapy)  boost  first 
started in the authors’ institution [7]. This approach is 
also  known  as  simultaneous  integrated  boost  (SIB)  in 
other institutions.  
Maximum  intensity  projection  (MIP)  images  from 
4D CT  scans  were  used  for  delineating  targets  in  the 
lung. For many patients, tumour/organ motion data were 
obtained using 4D CT with patients immobilised in the 
body  cast.  There  was  only  minimal  motion  with  bony 
lesions including spine and pelvis when the patients were 
placed  in  the  supine  position.  This  was  confirmed  by 
doing 4D CTs on the first few bony metastasis patients. 
These  bony  lesions  were  readily  targeted  for  SBRT 
because of minimal motion and easy visualisation with 
the  Novalis  stereoscopic  X rays.  For  anatomical  sites 
without good bony landmarks (e.g. kidney and liver), the 
placement  of  radio opaque  markers  e.g.  Visicoils
TM 
(RadioMed  Corporation,  Tyngsboro,  MA)  helps  in 
measuring motion and providing image guidance during 
treatment delivery.  
The size of lesions treated varied from less than 10 
cc to over 200 cc. Table 1 shows the distribution of size 
for GTVs. 
GTVs  (or  internal  target  volume  (ITV),  including 
internal motion as determined by 4D CT) were expanded 
2 3  mm  uniformly  to  account  for  setup  error.  One 
exception was vertebral lesions that were not expanded 
into  the  cord  space  so  that  the  spinal  cord  could  be 
spared. A rib lesion was expanded 5 mm; image guided 
setup error could be larger for peripheral targets, and no 
critical  structures  were  put  at  risk  by  this  expansion. 
Expansions  were  also  limited  when  they  became  non 
physical,  e.g.  if  planning  target  volume  (PTV)  would 
extend  outside  the  patient.  One  lesion  received  no 
expansion because the GTV was already larger than ideal 
for SBRT (280 cc). 
Treatment planning and delivery 
Individualised  tumour/organ  motion  data  obtained 
using 4D CT contributed to PTV. Multiple fields (5 12) 
of either dynamic conformal arcs or intensity modulated 
radiation  therapy  (IMRT)  were  used  to  maximize  the 
treatment conformality to the tumour and the avoidance 
of normal tissues. IMRT is preferred for target sites that 
showed  minimal  motion  such  as  osseous  sites.  Both 
coplanar and non coplanar approaches have been used. 
Dose  constraints  have  been  placed  on  partial  organ 
volume  based  on  existing  protocols  and  published 
literature [16 19], e.g. 700 cc liver receiving 15 Gy or 
less  in  three  fractions  [16],  no  more  than  10%  of  the 
adjacent spinal cord receiving 10 Gy [17], no part of the 
esophagus, stomach or small bowels receiving 8 Gy or 
more per fraction, central tracheo bronchial trees or large 
vessels receiving no more than 8 Gy per fraction as well 
as  V20  of  the  lung  is  10 15%  [19].  All  the  SBRT 
planning and QA was performed by two board certified 
medical physicists. The treating radiation oncologist and 
medical physicist were both present to ensure the most 
optimal  image guidance  with  kV stereoscopic  images 
overlaid on the digitally reconstructed radiographs (DRR) 
before each SBRT fraction.  
Dose regimens are dependent on tumour volume and 
constraint of normal tissues. This is the initial experience 
with  most  prescriptions  of  8  Gy  x  3  fx,  with  a  few 
exceptions.  Dose  escalation  trials  are  ongoing.  One 
patient  received  8  Gy  x  1  fx  as  a  boost  to  previously 
treated  (spine)  lesions.  Another  patient  with  3  small 
lesions (2.7, 1.9 and 40 cc) received 14 Gy x 1 fx to one 
lesion and 12 Gy x 1 fx to each of the other two. As 
discussed elsewhere, one patient received a 4 Gy x 3 fx 
concomitant  boost  to  the  PET positive  region  of  the 
primary  kidney  tumour.  The  last  two  patients  in  this 
series received higher doses, 8 Gy x 4 fx. 
Generally  95 100%  of  the  GTV  received  the  full 
prescription dose. The exception was the single fraction 
boost treatments (8 Gy x 1 fx), where coverage had to be 
compromised because of the prior dose to the spinal cord. 
Dose  homogeneity  was  fairly  high.  Again,  with  three 
exceptions GTV minimum dose (to a single voxel) was 
at least 93% of the prescription, while “hot” spots ranged 
from 103% to 112%. Naturally, PTV coverage was not 
as good, but with small margins and fairly homogeneous 
dose distributions, was not much different than the GTV 
coverage. 
Table 1  Distribution of GTV size. 
GTV (cc)  Number of lesions 
0 10  3 
10 40  11 
40 80  5 
80 150  3 
150 200  2 
>200  1 
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RESULTS 
All of the patients were treated with SBRT using the 
Novalis  stereoscopic  X ray  based  system.  Median 
follow up was nine months. The dose ranges from 24 to 
40 Gy in 3 6 fractions over 1 2 weeks. A representative 
SBRT  dose volume  histogram  (DVH)  as  shown  in 
Figure 3 demonstrates the high dose to the targets while 
minimising the dose to the critical surrounding structures. 
In  comparison  to  the  very  high  dose  received  by  the 
tumour target in the spine, normal tissues (spinal cord, 
kidney and liver received very low dose because of the 
rapid  fall off.  Figure  4  illustrates  the  SMART  boost 
approach: PET avid area received a higher fraction size 
(12 Gy) while the rest of the mass on CT (non avid on 
PET) received lower fraction size (8 Gy) to total doses of 
36 Gy and 24 Gy respectively in three fractions. Note the 
rapid fall off in the isodose lines. Figure 5 illustrates a 
bony  site  treated  with  SBRT  and  the  image guidance 
stereoscopic X rays that show excellent alignment.   
Patients’ tolerance 
All  of  the  patients  were  treated  in  the  supine 
position. The treatment time for SBRT is longer when 
compared  to  that  of  the  conventional  radiotherapy 
because of set up, image guidance and re alignment as 
well as multiple treatment fields and larger monitor units 
for high radiation dose. Despite the longer treatment time, 
all  patients  tolerated  SBRT  treatment  well.  Typical 
treatment  time  ranged  from  30  minutes  to  one  hour. 
Patient comfort is a key factor. The patients were asked 
to  continue  their  pain  medications  during  SBRT  as 
longer treatment time is expected. For some patients who 
presented  with  severe  pain  on  a  more  urgent  basis, 
conventional radiotherapy was started immediately for a 
few  fractions  to  provide  pain  relief  with  SBRT,  after 
which  their  pain  was  better  controlled.  Those  patients 
were  not  included  in  this  study.  Full course  SBRT  is 
preferred especially for patients with more radioresistant 
tumour,  e.g.  RCC,  whereby  higher  fraction  size  may 
have positive impact on local tumour control.  
Treatment outcome 
Thirteen  of  the  14  patients  (93%)  who  received 
SBRT  to  extra cranial  metastases  achieved  significant 
pain relief. All the patients received narcotics analgesics 
prior to SBRT and they (except one) responded well to 
the  treatment  with  significant  pain  relief  and  had 
declining need for narcotics analgesics. The only patient 
who did not have good pain relief had residual disease in 
the spine after surgery and radio frequency ablation. His 
pain  may  have  been  due  to  a  combination  of  residual 
disease  and  post operative  complications.  The  patients 
were observed to have achieved faster and more durable 
pain relief, sometimes even after one or two fractions of 
SBRT  as  compared  to  the  conventional  standard 
fractionation  scheme.  The  patients  who  achieved 
significant  pain  relief  also  reported  improvement  in 
quality  of  life  and  a  decrease  in  the  use  of  pain 
medications. There was no significant (grade 2 or higher) 
treatment related toxicity using RTOG/EORTC toxicity 
criteria observed in all patients. 
Follow up imaging revealed excellent local control 
rates after SBRT. Figure 6 shows significant reduction of 
a solitary paratracheal/paraesophageal mass 6 weeks post 
SBRT in a patient  with  metastatic RCC. The patient’s 
symptoms of dysphagia and odynophagia also improved 
significantly. Local control is defined (RECIST criteria) 
as radiologically stable disease (SD), or partial response 
(PR) or complete response (CR). Two patients had local 
progression. There was no CR. The remaining patients 
had  either  PR  or  SD.  The  two  local  progressions 
occurred  at  one  month  and  three  months  respectively 
post SBRT, yielding a local control rate of 87%. Target 
delineation was particularly difficult in one patient due to 
post operative changes and “hardware placement” in the 
spine. Target volume was very large in another patient 
and the delivered dose was also limited by the adjacent 
 
Figure 6  CT slice showing resolution of paratracheal/paraesophageal mass after image guided SBRT.  Left image 
is pre treatment while right is post treatment. 
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critical structures of small bowels and spinal cord. In the 
two patients  with primary  RCC, tumour size remained 
unchanged  but  their  pain  improved  and  their  renal 
function was unchanged post SBRT. 
DISCUSSION 
RCC  accounts  for  approximately  2%  of  all  new 
cancer incidences worldwide. The incidence of RCC has 
been increasing steadily and may be due in part to better 
detection through increased use of CT or MRI imaging 
studies. Epidemiologic studies are still needed to identify 
the real reasons for this rise [8]. Nearly half the patients 
with RCC have metastatic disease on presentation or will 
have a recurrence [9]. Treatment of metastatic RCC is 
important. Recently, two multi targeted tyrosine kinase 
inhibitors  i.e.  sunitinib  and  sorafenib,  have  been 
approved for treatment of metastatic RCC. Patients with 
metastatic RCC are living longer and thus local therapy 
such  as  radiotherapy  has  become  more  important 
especially in addressing symptomatic metastatic lesions.  
RCC is traditionally thought to be a radio resistant 
malignancy. It is believed that conventional radiotherapy 
does  not  have  a  role  in  the  definitive  management  of 
RCC  as  there  is  no  survival  benefit  of  adding 
radiotherapy  to  the  nephrectomy  bed.  Conventional 
radiotherapy has, however, been shown to be effective in 
palliating most sites of metastatic RCC including lung, 
bone and soft tissues in approximately 50% of patients 
[1]. On the other hand, SRS has been shown to provide a 
very high local control rate of up to 95% in various series 
[2 5]. This suggests that RCC may not be truly “radio 
resistant” but more likely to be “radio resistant” to lower 
fraction  sizes.  SBRT,  as  defined  by  the  American 
Society  of  Therapeutic  Radiology  and  Oncology  and 
American College of Radiology practice guidelines as a 
“treatment method to deliver a high dose of radiation to 
the target, utilising either a single dose or a small number 
of fractions with a high degree of precision within the 
body” [10], is ideal to be utilised in patients with “radio 
resistant” RCC. SBRT with the capability to deliver high 
dose  per  fraction,  is  made  feasible  by  the  recent 
refinement in precise IGRT and stereotaxis technology. 
In contrast to other local therapeutic modalities such as 
radio frequency  ablation,  surgery  and  cryotherapy, 
SBRT  offers  the  only  non invasive,  highly  efficient 
means  of  eradicating  discreet  tumour  foci  either  at  a 
primary  or  metastatic  site.  In  addition,  high  ablative 
radiation dose has been shown to be effective in treating 
human RCC in animal models.[11] 
This  retrospective  study  further  confirms  the 
efficacy of SBRT in the treatment of  metastatic RCC. 
Pain relief and local control were observed in 93% and 
87%  of  patients,  respectively.  The  results  compare 
favorably  to  those  using  conventional  radiotherapy  [1] 
but are consistent with the more recent findings utilising 
SBRT for metastatic RCC. A local control rate of 90 
98%  was  noted  in  a  retrospective  study  involving  58 
patients (50 patients with metastatic RCC and 8 patients 
with inoperable primary RCC) [12]. In another series of 
48  patients  with  60  RCC  metastatic  lesions  involving 
various levels of spine, Gerszten and colleagues showed 
that pain was controlled in 89% of patients [13]. The two 
patients with medically inoperable primary RCC also did 
well  with  pain  relief  and  stable  disease  on  imaging. 
Beitler  and  colleagues  also  reported  a  series  of  nine 
patients  with  primary  RCC  treated  with  SBRT.  There 
were four long term survivors (minimum follow up of 48 
months)  noted  [14].  Similar  results  were  seen  in  five 
patients with primary RCC treated with SBRT and had a 
follow up of more than 4 years [12]. 
Essentially no significant treatment related toxicity 
was noted in patients with metastatic RCC and primary 
RCC treated with SBRT in all reported series including 
the  current  report  [12 14].  This  is  likely  due  to  the 
precise  delivery  of  high dose  radiation  and  the  use  of 
stereotactic and IGRT technology. Because of rapid fall 
off in the isodose lines, only very limited normal tissues 
beyond tumour target received high dose radiation. Also, 
as encouraging as very low toxicity in various organs, 
there  was  no  deterioration  of  renal  function  including 
renal  function  tests  and  renal  scans  in  patients  whose 
primary RCC received SBRT. SBRT may offer a non 
invasive nephron sparing curative treatment modality for 
small RCC. SBRT may also play a role in patients with 
recurrent  RCC  in  the  remaining  kidney,  of  which 
preservation of renal function is of utmost importance. 
A few issues need to be mentioned and await further 
investigations.  The  response  to  SBRT  was  not  seen 
clearly  on  conventional  imaging  such  as  CT  images. 
Many  patients  showed  complete  pain  relief  and  stable 
disease on CT in the follow up. The same observation 
was  also  made  by  Wersall  and  colleagues  [12]. 
Functional  or  molecular  imaging  with  PET/CT  with 
novel radio pharmaceuticals may be more beneficial in 
assessing  response  to  SBRT.  The  α/β  of  primary  and 
metastatic  RCC  is  not  known.  Ning  and  colleagues 
determined the α/β values for RCC cell lines A498 and 
Caki 1  to  be  2.6  and  6.92,  respectively[15]  while 
DiBiase and colleagues used an α/β value of 10 for BED 
calculation. More work is required in order to determine 
the  most  appropriate  α/β  and  BED  values  for  RCC 
especially using the SBRT approach. Whether the use of 
SMART or SIB approach will have positive impact will 
also require further investigation. 
The limitations of this study are the small number of 
patients and short follow up. Some patients have widely 
metastatic disease and the SBRT was used to treat the 
fastest growing lesion or the most symptomatic lesions. 
The short follow up was also partly due to some of the 
patients  having died from the systemic disease despite 
the local control of the SBRT treated lesion. Despite all 
the patients having metastatic RCC, multiple sites were 
treated involving head and neck, chest, abdomen, bone 
and lungs, as well as the tumour masses of various sizes, 
contributing  to  a  heterogenous  group  of  patient 
population.  Various  fractionation  schedules  were  used 
mainly  because  of  the  dose  constraint  placed  on  the 
surrounding normal structures. It is difficult to determine 
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the  best  SBRT  fractionation  schedule  because  of  the 
heterogeneity in the dose used. If hypoxia is one of the 
important factors determining “radioresistance” in RCC, 
longer fractionation schedules with moderate high dose 
fraction  beyond  5 6  fractions  may  be  better  than  1 3 
fractions  with  ultra high  dose  fraction.  Despite  all  the 
above mentioned  shortcomings,  the  initial  experience 
has  been  encouraging.  Prospective  clinical  trials  are 
ongoing to address the best SBRT schedule for specified 
metastatic site and primary RCC in the affected kidney. 
Combining  SBRT  with  novel  targeted  therapy  such  as 
tyrosine  kinase  inhibitors  and  mTOR  inhibitors  to 
maximize both local and systemic control is also planned. 
CONCLUSIONS 
SBRT provides excellent local control and symptom 
palliation,  without  significant  toxicity.  SBRT  may 
represent a novel non invasive, nephron sparing option 
for the treatment of primary RCC as well as extra cranial 
metastatic RCC.  
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Figure 1  (a) The Brainlab Novalis stereotactic linear accelerator includes two orthogonal diagnostic x ray tubes 
and flat panel imagers to provide image guided 3D patient alignment. (b) Example of Novalis image 
alignment.  Upper left panel is DRR showing expected image (from one of the two imagers).  Upper 
right panel shows actual X ray.  Lower left panel shows overlay of the DRR and X ray image.  This 
information from the two orthogonal X ray systems plus full CT data set for computation of DRRs 
allows calculation of patient shift to produce correct alignment.  The post shift image overlay is shown 
in the bottom right panel.  Note the quality of the image alignment both by the bony landmarks and the 
implanted fiducial markers. 
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Figure 2  (a) Patient immobilisation using an aquaplast head and neck mask.  Reflective markers on the mask are 
utilised by the Novalis infrared tracking system for both initial patient alignment as well as incremental 
shifts. (b) Patient immobilisation using a vacuum body mold.  Reflective markers are again used by the 




Figure 3  Dose volume histograms (DVHs) from a spine treatment plan.  Upper left panel shows target coverage 
(18Gy prescribed dose).  Upper right panel shows DVH for the spinal cord near the target (from 6mm 
superior to 6mm inferior to target).    Bottom panels show other organs at risk, left kidney (left) and 
liver (right). 
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Figure 4  Treatment plan with SMART boost.  8 Gy prescribed to renal mass, with 12 Gy (total) going to volume 





Figure 5  Pre  and post alignment images for treatment of rib metastasis.  Top panels show overlay of orthogonal 
X rays (blue) with their expected DRRs (amber).  Bottom panels show final alignment based on bony 
anatomy. 
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